GSK Pharma fixes June 23 record date for 101st AGM
GlaxoSmithKline Pharmaceuticals Limited has fixed June 23, 2026, as the record date to determine eligibility for its 101st Annual General Meeting, which will be held on June 30, 2026, at 11.00 a.m. via video conferencing. The company reported a revenue of ₹3,790 crore for FY26, with PAT excluding exceptional items exceeding ₹1,010 crore. Shareholders can vote via remote e-voting from June 26 to June 29, 2026.
*this image is generated using AI for illustrative purposes only.
GlaxoSmithKline Pharmaceuticals Limited has fixed Tuesday, June 23, 2026, as the record date to determine shareholder eligibility for the 101st Annual General Meeting (AGM). The AGM is scheduled for Tuesday, June 30, 2026, at 11.00 a.m. via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The company reported a revenue of ₹3,790 crore for FY26, a 2% increase from the previous year, with Profit After Tax (PAT) excluding exceptional items crossing ₹1,010 crore for the first time.
The meeting will be conducted without a physical venue in compliance with the Companies Act, 2013, and relevant SEBI (Listing Obligations and Disclosure Requirements) Regulations. Shareholders participating through VC/OAVM will be counted for quorum purposes under Section 103 of the Companies Act, 2013. The Annual Report for the Financial Year 2025-26 has been sent electronically to shareholders with registered email addresses, with a letter dispatched on June 6, 2026.
Remote E-Voting Schedule
Remote e-voting will commence at 9.00 a.m. on Friday, June 26, 2026, and conclude at 5.00 p.m. on Monday, June 29, 2026. Shareholders holding shares as of the cut-off date, Tuesday, June 23, 2026, are eligible to vote. The facility is provided by NSDL.
Business to be Transacted
The Board has proposed the ratification of remuneration for Cost Auditor R. Nanabhoy & Company. The fees for auditing cost records are set at ₹8.02 Lakhs for the year ended March 31, 2026, and ₹8.42 Lakhs for the year ending March 31, 2027, exclusive of taxes and out-of-pocket expenses. Additionally, the company seeks shareholder approval to pay commission to non-Whole-time Directors for a five-year period from April 1, 2026, to March 31, 2031, subject to a ceiling of 1% of net profits.
| Business Item | Details |
|---|---|
| AGM Date | June 30, 2026 |
| AGM Time | 11.00 a.m. |
| Record Date | June 23, 2026 |
| E-Voting Start | June 26, 2026 |
| E-Voting End | June 29, 2026 |
| Cost Auditor Fees (FY26) | ₹8.02 Lakhs |
| Cost Auditor Fees (FY27) | ₹8.42 Lakhs |
Pursuant to SEBI directives effective November 18, 2025, dividend payments will be processed exclusively in electronic mode, discontinuing the use of dividend warrants or cheques. Shareholders holding shares in dematerialized form must update details with their Depository Participant, while those with physical holdings must submit the prescribed ISR-1 form to KFin Technologies Limited. The company has advised members to register or update email addresses and bank account mandates to ensure timely receipt of payouts.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE159A01016/689c24a13dc3460f.pdf
Historical Stock Returns for GlaxoSmithKline Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.34% | +2.59% | +11.24% | +3.12% | -27.43% | +63.67% |
Will the 2% revenue growth trend for FY26 persist into FY27, or are there catalysts for accelerated expansion?
How will the proposed five-year commission structure for non-Whole-time Directors impact overall corporate governance costs?
What strategic initiatives will management outline during the AGM to drive future profitability beyond the current levels?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
